Heng Xu's dataset analyzes the impact of China's National Drug Price Negotiation (NDPN) on pharmaceutical firms' innovation activities. It uses panel data from Chinese A-share listed pharmaceutical companies from 2010 to 2024, employing a multi-period difference-in-differences model. The dataset was last updated on May 11, 2026, and is shared under a CC-BY-4.0 license.
Use Cases
- Analyze the causal effect of drug price negotiation access on firm innovation investment based on the described panel data.
- Investigate heterogeneity in policy impact based on firm size and market power as described in the results.
- Study the structural divergence between strategic and substantive innovation outcomes (patent quantity vs. quality) as detailed in the analysis.
Strengths
- The analysis covers a 15-year time range from 2010 to 2024.
- The methodology includes robustness tests like parallel trend tests, placebo tests, and PSM-DID.
- The dataset is licensed for open use under CC-BY-4.0.
Limitations
- Column-level documentation is absent; field semantics must be inferred after download.
- Row count is unknown, which may limit suitability assessment.
- The dataset is small in scale at 753.1 KB, indicating limited data volume.
Provenance
- Source
- figshare
- Collection Method
- Panel data from Chinese A-share listed pharmaceutical companies, analyzed via multi-period difference-in-differences model.
- Time Range
- 2010 to 2024
- Freshness
- Last updated 2026-05-11 05:28:41; freshness should be verified.
- Geography
- China